Share This Page
Drugs in ATC Class A10BF
✉ Email this page to a colleague
Drugs in ATC Class: A10BF - Alpha glucosidase inhibitors
Market dynamics and patent landscape for ATC Class A10BF (alpha-glucosidase inhibitors): who owns the IP, when exclusivity ends, and where generic and biosimilar risks concentrate
ATC Class A10BF (alpha-glucosidase inhibitors) is a niche within oral diabetes. IP is concentrated in a small number of originators and is increasingly time-limited by old compositions and follow-on formulation/process patents expiring across the 2020s. The practical competitive battleground is not molecule-level novelty, but country-by-country Orange Book and local-registration status for specific solid-dose forms and manufacturing methods, plus second-line “maintenance” patents that can delay generic entry only where they are still in force.
The active ingredient set that historically defines A10BF is led by acarbose; miglitol is a second major member of the class; voglibose is commercially important in parts of Asia. Most foundational composition-of-matter and early-use IP is expired in major markets, shifting enforcement to (1) formulation/process patents (granulation, tableting, stability, impurity controls), (2) method-of-treatment claims (dose/titration and therapeutic use patterns where still patented in a given jurisdiction), and (3) regulatory data exclusivity and product-specific exclusivity where applicable.
ATC Class scope and commercial carriers
A10BF alpha-glucosidase inhibitors typically covers:
- Acarbose (originators historically include Bayer entities)
- Miglitol (originators historically include smaller specialty pharma groups in multiple markets)
- Voglibose (stronger regional footprint in Asia)
Because patent estates are jurisdiction-specific and product-specific (brand, dosage form, and strength), a robust “market dynamics + patent” view is best built around the regulated product entries and listed patents in each target country, rather than around the ATC class as a whole.
What patents protect acarbose and other alpha-glucosidase inhibitors under A10BF?
Short answer: Most blocking patents are not broad composition-of-matter anymore in the US/EU; the remaining leverage is in formulation and process IP tied to a specific marketed product. Any active blocking estate depends on the jurisdiction and dosage form.
Where patent scope is most durable: formulation and manufacturing method
For established oral solids like acarbose/miglitol/voglibose, patenting tends to concentrate on:
- Granulation and tableting processes that manage particle size distribution, hardness, dissolution, and stability
- Impurity and degradation control (specified limits for key impurities, storage-induced byproducts)
- Coated or modified-release variants (where markets have such products)
- Stabilized formulations with defined excipient systems
These patents can be meaningful if:
- they are still active in the jurisdiction at the time of generic filing, and
- they map cleanly onto what the generic intends to make.
What patent claims are typically asserted in this class
Typical claim clusters in alpha-glucosidase inhibitor estates:
- Composition claims for specific excipient ratios or stabilized blends
- Process claims for blending, granulating, drying, milling, or compression steps
- Method-of-use claims with a specific dosing regimen or titration algorithm
- Package and stability-related claims (less common, but still seen in some jurisdictions)
When do alpha-glucosidase inhibitor exclusivities end (acarbose, miglitol, voglibose)?
Short answer: Foundational IP is generally expired; remaining exclusivity windows are dominated by product-specific formulation/process patents, plus regulatory exclusivity mechanisms that differ by region and pathway.
US practical timeline dynamics (Orange Book model)
For the US:
- Composition-of-matter patents for these old molecules largely expired decades ago.
- Generics typically rely on ANDA pathways with Paragraph IV certifications only when unexpired patents exist in the Orange Book for a particular listed NDA/ANDA reference product.
- “Exclusivity” in the US can come from periods tied to approvals, not only from composition patents, but for well-established oral solids those approval-based exclusivity periods are usually long elapsed.
EU/UK EPO model
In Europe:
- Supplementary Protection Certificates (SPCs) can extend specific composition patent terms for active ingredients, but for older molecules these extensions have largely run out across major countries.
- Any remaining block tends to be from EPs covering specific formulations/process steps.
What generic entry risks exist for A10BF alpha-glucosidase inhibitors?
Short answer: Entry risk is low for the base molecules where no current patent listings remain for the specific reference product. Risk spikes where:
- a reference product still has active Orange Book listed patents, and
- the generic must prove “no infringement” or achieve a “skinny label” around a patented method-of-use.
US generic scenarios that matter
- ANDA without Paragraph IV: if there are no unexpired listed patents for the reference product at filing time.
- Paragraph IV: if at least one patent listed for the reference product is unexpired and the ANDA applicant chooses to challenge it.
- Section viii vs 505(b)(2) dynamics: formulation or alternative use products can affect what patents are listed and what certifications are required.
Paragraph IV leverage for formulation and method-of-use claims
Even for old molecules, a formulation patent can support a Paragraph IV challenge framework if it remains listed and the generic does not design around it. Method-of-use claims can be more challenging, but often are less cleanly enforced unless the label is also constrained in the generic submission.
What is the Orange Book status of acarbose, miglitol, and voglibose in the US?
Short answer: A complete Orange Book status requires product-by-product listing data (NDA/ANDA number, strength, dosage form, and each listed patent’s expiration and patent use code). Without that dataset for the specific reference products and strengths, a definitive “Orange Book status” map for A10BF cannot be produced accurately.
Practical implication for diligence
For market entry or licensing:
- build a table by reference product (NDA/ANDA) and strength/dosage form
- extract all listed patents
- tag each patent as composition vs method vs formulation/process
- link each to intended generic manufacturing and labeling
Without the underlying Orange Book listing records, any “status” statement would be speculative.
How strong is the patent estate for acarbose versus miglitol versus voglibose?
Short answer: For all three, estate strength is generally modest at the class level; the differentiator is whether any specific formulation/process patents remain active in a target jurisdiction for the particular branded or reference-listed products.
Relative strength is driven by:
- How many follow-on patents are still active
- Whether patents cover generic-implementable manufacturing steps
- Whether method-of-use claims remain compatible with a label carve-out
- Enforcement history and willingness to litigate
Deal and litigation readiness
The more relevant “strength” metric for business decisions is:
- number of still-unexpired patents tied to the reference product,
- remaining time-to-expiration for each,
- and whether claimed features are easy to design around.
At a class level, alpha-glucosidase inhibitors have fewer structural “last-mile” barriers than newer diabetes classes (GLP-1, SGLT2, DPP-4), where active ingredient innovation is still generating large estates.
What formulation patents protect alpha-glucosidase inhibitors (granules, tablets, stability)?
Short answer: Residual IP is most commonly about stabilizing acarbose-like actives and controlling dissolution/impurity profiles for oral tablets. Protection typically covers excipient systems and process parameters.
Patent-to-formulation mapping used in freedom-to-operate (FTO)
When evaluating a generic:
- compare particle size and dissolution targets
- compare excipient systems for instability or impurity formation
- check manufacturing steps that affect degradation (drying temps, residence times)
- confirm impurity specification strategies against the claimed limits
Which companies are challenging or litigating alpha-glucosidase inhibitor patents?
Short answer: Litigation and challenge activity is intermittent and jurisdiction-specific; alpha-glucosidase inhibitor disputes typically involve ANDA Paragraph IV filings tied to remaining formulation/process patents, not broad composition battles.
A complete and accurate “who is challenging what” list requires:
- docket-level access to filings,
- mapping to the Orange Book patents per reference product,
- and jurisdiction filtering.
Absent that litigation dataset, listing companies without verification would be unreliable.
What patent litigation affects generic entry for A10BF drugs?
Short answer: Where litigation exists in this class, it usually delays entry only when the challenged patents are still unexpired and not easily design-around by formulation or manufacturing changes.
Key litigation mechanics that matter for alpha-glucosidase inhibitors:
- trigger from Paragraph IV (US) based on listed patents
- settlement terms that can include:
- agreed entry dates,
- permitted manufacturing changes,
- and label or product design constraints
How do licensing deals and settlements shape market timing for alpha-glucosidase inhibitors?
Short answer: Settlement agreements can shift the effective generic entry date, especially when formulation/process patents are still active. In practice, the market outcome is usually “pay-for-delay only if the parties settle,” and otherwise a standard design-around or validity challenge path.
Settlement levers that matter commercially
- Entry date: when the generic can launch in the country
- Product scope: which strengths and dosage forms are covered
- Design-around constraints: limitations tied to process parameters or excipient composition
- Label changes: carve-outs around any method-of-use claims (where relevant)
How does A10BF compare with other diabetes classes on IP longevity and generic risk?
Short answer: A10BF generics typically face fewer “new molecule” blocking estates than GLP-1, SGLT2, and DPP-4 inhibitors, whose active ingredient innovation created broader and newer patent thickets. A10BF’s risk profile is “residual formulation/process patents,” not “active ingredient innovation.”
Business implication
- R&D spend for A10BF is usually oriented to:
- manufacturing efficiency,
- stability and impurity control,
- and cost-of-goods reductions, rather than to breakthrough differentiation protected by long-dated core patents.
Key Takeaways
- A10BF alpha-glucosidase inhibitors (mainly acarbose, with miglitol and voglibose in key regions) have largely time-limited class-level IP; remaining barriers are product-specific formulation/process patents.
- Exclusivity timelines and Orange Book status are the practical determinants of generic entry in each target jurisdiction.
- Generic entry risk is concentrated where unexpired listed patents still cover a specific reference product’s dosage form or method-of-use, and where design-around is constrained by claimed manufacturing/formulation features.
- Litigation and settlements, when they occur, usually affect timing through still-unexpired listed patents, not through broad composition-of-matter enforcement.
FAQs
-
What determines whether a generic can file an ANDA without Paragraph IV for acarbose products?
Whether the specific reference product (NDA/ANDA) has any unexpired Orange Book listed patents at the time of filing. -
Which patent claim types most often block alpha-glucosidase inhibitor generics after composition patents expire?
Formulation and manufacturing method claims that tie directly to the marketed dosage form and impurity/stability targets. -
Do method-of-use claims materially affect label-based generic launches for A10BF drugs?
They can, but the impact depends on whether the unexpired claims map to a labeled dosing regimen that a generic would need to replicate or carve out. -
Are formulation variants (strength-specific or excipient-specific) treated as separate patent estates in practice?
They can be, because Orange Book listings and jurisdictional protection are often product and strength tied. -
How should investors size the revenue exposure of a generic threat in A10BF?
By indexing the expected generic entry date to the last unexpired listed patent for the specific reference product and strength in each target market.
References
- European Medicines Agency. EPAR pages and public assessment reports for alpha-glucosidase inhibitors (acarbose, miglitol, voglibose).
- FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations (product-by-product NDA/ANDA patent listings).
- United States Patent and Trademark Office (USPTO). Patent full-text and bibliographic records for acarbose/miglitol/voglibose related formulation and process claims.
- Espacenet (EPO). Patent family and legal status data for alpha-glucosidase inhibitor inventions.
More… ↓
